SLXN
Silexion Therapeutics Corp (SLXN) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at C for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B+ (3.7) | D+ (1.8) | C+ (2.8) | F (0.3) | C+ (2.6) | C (2.3) |
| 2026-11-07 | A- (3.9) | C- (1.9) | C+ (2.8) | F (0.3) | C+ (2.7) | C (2.3) |
| 2026-10-31 | B+ (3.7) | D+ (1.8) | C+ (2.8) | F (0.3) | C+ (2.7) | C (2.3) |
| 2026-10-24 | C+ (2.5) | C- (1.9) | C+ (2.8) | F (0.3) | C+ (2.6) | C- (2.0) |
| 2026-10-17 | C+ (2.5) | D+ (1.8) | C+ (2.8) | F (0.3) | C+ (2.6) | C- (2.0) |